EUVIMED · CrossrefZeitschrift
The Lancet Infectious Diseases
ISSN 1473-3099 · Elsevier BV
Neueste Artikel
Quantifying how multiple transmission routes contribute to the spread of HTLV-1 in different endemic foci: a mathematical modelling study
A fatal case of Legionella micdadei prosthetic valve endocarditis diagnosed by plasma microbial cell-free DNA metagenomic sequencing
Size of the 2026 Ebola outbreak and risk of cross-border spillover from Bundibugyo virus in Ituri Province, DR Congo, and its implications for preparedness: a recalibrated stochastic modelling study
Combination antiviral treatment for a patient with lymphocytic choriomeningitis virus meningoencephalitis associated with bispecific antibody teclistamab therapy for myeloma
Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial
Imipenem–cilastatin–funobactam versus imipenem–cilastatin–relebactam in patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia: a phase 3, double-blind, non-inferiority randomised trial
Maternal and perinatal outcomes in pregnant women with Lassa fever: analysis from the LASCOPE prospective cohort study
Humoral immunity after mRNA SARS-CoV-2 XFG vaccination
Funobactam for hospital-acquired pneumonia and ventilator-associated pneumonia: promising evidence, unanswered questions
Andes virus management—balancing infection control with patient safety and autonomy
Correction to Lancet Infect Dis 2026; 26: 1010–21
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial
Understanding and exploiting superspreading to disrupt Mycobacterium tuberculosis transmission
Effect of a community-based behavioural intervention bundle to improve antibiotic use and patient management in Burkina Faso and DR Congo (CABU-EICO): a cluster-randomised controlled trial
Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study
Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime–zidebactam alongside phage therapy in the USA
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial
A rifamycin-free regimen for shortened tuberculosis treatment
Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial
Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia
A systematic review of Nipah virus disease epidemiological parameters, outbreaks, and mathematical models
Expert consensus on case definitions in human loiasis: a Delphi study
Can better oral care reduce non-ventilator hospital-acquired pneumonia?
Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons
Mpox: virus expansion, evolution, and immune recognition
Understanding the common cold
Correction to Lancet Infect Dis 2024; 24: 763
Lymphoma-like endoscopic appearance of lymphogranuloma venereum
Antibody evasion and receptor binding of SARS-CoV-2 variants PQ.16.1.1 and RK.1
EUVIMED